nVerses Capital’s Aquestive Therapeutics AQST Stock Holding History

nVerses Capital’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,700	Closed	-$28.4K	–	63
2024 Q3	$28.4K	Buy	+5,700	New	+$22.2K	0.01%	748

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

nVerses Capital's AQST Position: Q4 2024 in Review

nVerses Capital sold out of Aquestive Therapeutics (AQST) in Q4 2024, closing a stake of 5,700 shares — an estimated $28.4K sold.

nVerses Capital first reported a position in AQST in Q3 2024 and held it in 1 quarter. The position peaked at $28.4K in Q3 2024. 114 funds tracked by Wall St. Rank hold AQST as of Q4 2024.

nVerses Capital reported no remaining Aquestive Therapeutics position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 5,700 Aquestive Therapeutics shares in Q4 2024, an estimated $28.4K.
nVerses Capital first reported a position in Aquestive Therapeutics in Q3 2024 and held it in 1 quarter.
nVerses Capital's Aquestive Therapeutics position peaked at $28.4K in Q3 2024.
114 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.